title: The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
abstract: Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPI(B) (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPI(B) is feasible.
authors.affiliation: Department of Hematology, Rigshospitalet, Copenhagen, Denmark. christian.geisler@rh.regionh.dk
authors.forename: Christian H
authors.initials: CH
authors.lastname: Geisler
authors.forename: Arne
authors.initials: A
authors.lastname: Kolstad
authors.forename: Anna
authors.initials: A
authors.lastname: Laurell
authors.forename: Riikka
authors.initials: R
authors.lastname: Räty
authors.forename: Mats
authors.initials: M
authors.lastname: Jerkeman
authors.forename: Mikael
authors.initials: M
authors.lastname: Eriksson
authors.forename: Marie
authors.initials: M
authors.lastname: Nordström
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Boesen
authors.forename: Herman
authors.initials: H
authors.lastname: Nilsson-Ehle
authors.forename: Outi
authors.initials: O
authors.lastname: Kuittinen
authors.forename: Grete F
authors.initials: GF
authors.lastname: Lauritzsen
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ralfkiaer
authors.forename: Mats
authors.initials: M
authors.lastname: Ehinger
authors.forename: Christer
authors.initials: C
authors.lastname: Sundström
authors.forename: Jan
authors.initials: J
authors.lastname: Delabie
authors.forename: Marja-Liisa
authors.initials: ML
authors.lastname: Karjalainen-Lindsberg
authors.forename: Peter
authors.initials: P
authors.lastname: Brown
authors.forename: Erkki
authors.initials: E
authors.lastname: Elonen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D019394:Ki-67 Antigen / Q000096:biosynthesis; D020522:Lymphoma, Mantle-Cell / Q000378:metabolism / Q000401:mortality* / Q000628:therapy*; D008297:Male; D012307:Risk Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D019394:Ki-67 Antigen